Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro reported total revenue of $9.2 million for the quarter, up 17% from $7.9 million a year earlier, led by product revenue of $6.0 million (up 21%). Gross profit was $5.6 million with a 60% margin, slightly below prior-year margins. The company recorded a net loss of $5.8 million for the quarter (basic and diluted loss per share $0.21) and a six-month net loss of $11.9 million (EPS $0.42), driven by higher research and development, sales and marketing, and general and administrative expenses.
Liquidity strengthened to $41.5 million in cash and equivalents at June 30, 2025 after a registered direct equity sale that raised ~$3.3 million net and an initial note issuance that provided approximately $28.7 million net. The company entered a Note Purchase Agreement providing up to $105.0 million of potential notes (initial $30.0 million funded) secured by substantially all assets and carrying PIK interest and future revenue-sharing provisions; management states existing cash is sufficient for at least the next twelve months. Accumulated deficit totaled $203.2 million.